Basic Information
| LncRNA/CircRNA Name | MEG3 |
| Synonyms | NA |
| Region | GRCh38_14:100779410-100861031 |
| Ensemble | ENSG00000214548 |
| Refseq | NR_002766 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | qPCR, Western blot, RIP etc |
| Sample | prostate cancer and its adjacent tissues ,cell lines (PC3 and DU145) |
| Expression Pattern | differential expressed |
| Function Description | EN2 expression was inversely proportional to MEG3 in the prostate cancer tissues.LncRNA MEG3 facilitated H3K27 trimethylation of EN2 through binding to EZH2 in PC3 cells. |
| Pubmed ID | 31790140 |
| Year | 2019 |
| Title | LncRNA MEG3 Inhibits the Progression of Prostate Cancer by Facilitating H3K27 Trimethylation of EN2 Through Binding to EZH2 |
External Links
| Links for MEG3 | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |